Downregulation of immunological mediators in 2,4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions by hydrocortisoneloaded chitosan nanoparticles

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 5143-5156

  Hussain, Zahid ^a   Katas, Haliza ^a   Amin, Mohd Cairul Iqbal Mohd ^a   Kumolosasi, Endang ^a   Sahudin, Shariza ^b  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

Chitosan nanocarrier; Elastic fibers; Glucocorticoids; Topical delivery

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; CHITOSAN NANOPARTICLE; GAMMA INTERFERON; HISTAMINE; HYDROCORTISONE; IMMUNOGLOBULIN E; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; NANOPARTICLE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN A; ANTIINFLAMMATORY AGENT; CHITOSAN; CYTOKINE; DRUG CARRIER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; ELASTIC FIBER; FIBROBLAST; HISTAMINE RELEASE; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SKIN DEFECT; VISCOSITY; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DERMATITIS, ATOPIC; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; RANDOMIZATION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CHITOSAN; CYTOKINES; DERMATITIS, ATOPIC; DINITROFLUOROBENZENE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG CARRIERS; HYDROCORTISONE; MICE; NANOPARTICLES; RANDOM ALLOCATION;

EID: 84908519237     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S71543     Document Type: Article

References (32)

1. Alomar A, Berth-Jones J, Bos JD, et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol. 2004;151 Suppl 70: 3-27.
2. Şenyiğit T, Padula C, Ozer O, Santi P. Different approaches for improving skin accumulation of topical corticosteroids. Int J Pharm. 2009;380(1-2):155-160.
3. Schoepe S, Schäcke H, May E, Asadullah K. Glucocorticoid therapyinduced skin atrophy. Exp Dermatol. 2006;15(6):406-420.
4. Zöller NN, Kippenberger S, Thaçi D, et al. Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin model. Toxicol In Vitro. 2008;22(3):747-759.
5. Kaplun-Frischoff Y, Touitou E. Testosterone skin permeation enhancement by menthol through formation of eutectic with drug and interaction with skin lipids. J Pharm Sci. 1997;86(12):1394-1399.
6. Sammeta SM, Vaka SR, Murthy SN. Transcutaneous electroporation mediated delivery of doxepin-HPCD complex: a sustained release approach for treatment of postherpetic neuralgia. J Control Release. 2010;142(3):361-367.
7. Prausnitz M. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev. 2004;56(5):581-587.
8. Heuschkel S, Goebel A, Neubert RH. Microemulsions-modern colloidal carrier for dermal and transdermal drug delivery. J Pharm Sci. 2008;97(2):603-631.
9. Trotta M, Peira E, Debernardi F, Gallarate M. Elastic liposomes for skin delivery of dipotassium glycyrrhizinate. Int J Pharm. 2002; 241(2):319-327.
10. Fang YP, Huang YB, Wu PC, Tsai YH. Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behaviour. Eur J Pharm Biopharm. 2009;73(3):391-398.
11. Jenning V, Gysler A, Schäfer-Korting M, Gohla S. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm. 2000;49(3):211-218.
12. Wu H, Ramachandran C, Weiner ND, Roessler BJ. Topical transport of hydrophilic compounds using water-in-oil nanoemulsions. Int J Pharm. 2001;220(1-2):63-75.
13. Lademann J, Richter H, Teichmann A, et al. Nanoparticles-an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm. 2007;66(2):159-164.
14. Biruss B, Valenta C. Skin permeation of different steroid hormones from polymeric coated liposomal formulations. Eur J Pharm Biopharm. 2006;62(2):210-219.
15. Kuchler S, Radowski MR, Blaschke T, et al. Nanoparticles for skin penetration enhancement-a comparison of a dendritic core-multishellnanotransporter and solid lipid nanoparticles. Eur J Pharm Biopharm. 2009;71(2):243-250.
16. Wu X, Price GJ, Guy RH. Disposition of nanoparticles and an associated lipophilic permeant following topical application to the skin. Mol Pharm. 2009;6(5):1441-1448.
17. Hussain Z, Katas H, Mohd Amin MC, Kumolosasi E, Buang F, Sahudin S. Self assembled polymeric nanoparticles for percutaneous co-delivery of hydrocortisone/hydroxytyrosol: an ex vivo and in vivo study using an NC/Nga mouse model. Int J Pharm. 2013;444(1-2):109-119.
18. Grewe M, Bruijnzeel-Koomen CA, Schöpf E, et al. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today. 1998;19(8):359-361.
19. Leung DY. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol. 2000;105(5):860-876.
20. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol. 2005;6(2):135-142.
21. Zhang Y, Matsuo H, Morita E. Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis. Arch Dermatol Res. 2006;297(9):425-429.
22. Jung MK, Hur DY, Song SB, et al. Tannic acid and quercetin display a therapeutic effect in atopic dermatitis via suppression of angiogenesis and TARC expression in Nc/Nga mice. J Invest Dermatol. 2010;130(5):1459-1463.
23. Kang MJ, Eum JY, Park SH, et al. Pep-1 peptide-conjugated elastic liposomal formulation of taxifolin glycoside for the treatment of atopic dermatitis in NC/Nga mice. Int J Pharm. 2010;402(1-2):198-204.
24. Lee HS, Kim SK, Han JB, et al. Inhibitory effects of Rumex japonicus Houtt. on the development of atopic dermatitis-like skin lesions in NC/ Nga mice. Br J Dermatol. 2006;155(1):33-38.
25. Papadimitriou S, Bikiaris D, Avgoustakis K. Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohyd Polym. 2008;73(1):44-54.
26. El-Hefian EA, Elgannoudi ES, Mainal A, Yahaya AH. Characterization of chitosan in acetic acid: Rheological and thermal studies. Turk J Chem. 2010;34:47-56.
27. Clausen AE, Bernkop-Schnürch A. Thiolated carboxymethylcellulose: in vitro evaluation of its permeation enhancing effect on peptide drugs. Eur J Pharm Biopharm. 2001;51(1):25-32.
28. Matsuda H, Watanabe N, Geba GP, et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol. 1997;9(3):461-466.
29. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445-454.
30. Hussain Z, Katas H, Amin MCIM, Kumolosasi E, Sahudin S. Antidermatitic perspective of hydrocortisone as chitosan nanocarriers: an ex vivo and in vivo assessment using an NC/Nga mouse model. J Pharm Sci. 2013;102(3):1063-1075.
31. Tomimori Y, Tanaka Y, Goto M, Fukuda Y. Repeated topical challenge with chemical antigen elicits sustained dermatitis in NC/ Nga mice in specific-pathogen-free condition. J Invest Dermatol. 2005;124(1):119-124.
32. Suda N, Yu X, Kubo C. Dehydroepiandrosterone attenuates the spontaneous elevation of serum IgE level in NC/Nga mice. Immunol Lett. 2001;79(3):177-179.